Feldan Therapeutics Receives Investment from Zynext Ventures
Summary
The company intends to use the funds to expand operations and its R&D efforts. Led by CEO François-Thomas Michaud, Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the delivery of antisense oligonucleotides into cells, generating new therapies. the company’s pipeline expansion is focused on skin and lung diseases. Its lead product for BCC (FLD-103) is in a Phase 1/2a clinical trial.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected